Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis.
BACKGROUND
Recently, increasing relevant studies researched the efficacy of castration resistant prostate cancer (CRPC) patients using chemotherapy with or without estramustine, in order to assess the efficacy and toxicity of combining estramustine with chemotherapy for the treatment of CRPC.


METHODS
Relevant randomized clinical trials were systematically searched from the databases Pubmed, Embase, and Web of science up to April 1, 2016. Data were centrally extracted and analyzed from the previous studies by 2 independent reviewers. The primary endpoint was overall survival (OS) with pooled hazard ratios. Secondary endpoints were prostate-specific antigen (PSA) response and grade 3 or 4 toxicity using pooled odds ratios. Stata version 12.0 software was used for statistical analysis.


RESULTS
Overall, this meta-analysis identified 9 eligible articles, including a total of 956 patients, who had been accrued between January 1, 1993 and December 1, 2010 and randomly divided into chemotherapy with estramustine and without estramustine. Chemotherapy (with or without estramustine) consisted of docetaxel, paclitaxel, ixabepilone, epirubicin, and vinblastine. Patients who received chemotherapy with estramustine had a better improvement in PSA response rate, comparing those without estramustine (OR = 1.84, 95% CI = 1.20-2.80). However, OS between the 2 groups indicated no significant differences (HR = 0.90, 95% CI = 0.77-1.05). Besides, these results of meta-analysis showed no obvious differences between these 2 groups in grade 3 or 4 adverse effects, including anemia (OR = 0.78, 95% CI = 0.38-1.57), neutropenia (OR = 0.91, 95% CI = 0.59-1.43), thrombocytopenia (OR = 0.68, 95% CI = 0.19-2.42), nausea (OR = 2.34, 95% CI = 0.81-6.72), vomiting (OR = 2.43, 95% CI = 0.69-8.51), diarrhea (OR = 3.45, 95% CI = 0.93-12.76), fatigue (OR = 0.67, 95% CI = 0.32-1.41), neuropathy (OR = 0.54, 95% CI = 0.21-1.44), allergic reaction (OR = 1.60, 95% CI = 0.37-6.84), thromboembolic event (OR = 2.18, 95% CI = 0.86-5.51), and edema (OR = 1.02, 95% CI = 0.18-5.95).


CONCLUSIONS
This meta-analysis indicated chemotherapy with additional estramustine increased the PSA response rate. However, OS and grade 3 or 4 toxicity were not improved for these patients with CRPC.
aDepartment of Urologic Surgery, The Affiliated Cancer Hospital of Jiangsu Province of Nanjing Medical University bDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zhiqiang
Z
Qin
Xiao
X
Li
Jianzhong
J
Zhang
Jingyuan
J
Tang
Peng
P
Han
Zhen
Z
Xu
Yajie
Y
Yu
Chengdi
C
Yang
Chengming
C
Wang
Ting
T
Xu
Zicheng
Z
Xu
Qing
Q
Zou
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004961:Estramustine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000187:drug effects; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000401:mortality; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis
D004961:Estramustine; D017430:Prostate-Specific Antigen
Clin Prostate Cancer. 2004 Sep;3(2):104-11
15479494
J Clin Oncol. 2005 Mar 1;23(7):1439-46
15735119
N Engl J Med. 2004 Oct 7;351(15):1502-12
15470213
Cancer Res. 2011 Feb 15;71(4):1208-13
21285252
J Clin Oncol. 1999 Oct;17(10):3160-6
10506613
Stat Med. 1998 Dec 30;17(24):2815-34
9921604
Int Med Case Rep J. 2010 Apr 19;3:39-41
23754886
Trends Genet. 2004 Sep;20(9):439-44
15313553
Endocr Relat Cancer. 2012 Nov 09;19(6):R243-53
23033314
Ann Oncol. 2007 Jun;18(6):1064-70
17434899
Drugs Aging. 1995 Jul;7(1):49-74
7579781
Lancet Oncol. 2007 Nov;8(11):994-1000
17942366
Actas Urol Esp. 2014 Apr;38(3):184-91
24507454
Cancer. 2002 Mar 1;94(5):1457-65
11920502
N Engl J Med. 2004 Oct 7;351(15):1513-20
15470214
ScientificWorldJournal. 2008 Jun 13;8:586-97
18604442
Mol Pharmacol. 1994 Nov;46(5):866-72
7969073
BJU Int. 2008 Nov;102(9):1080-5
18485028
Nat Genet. 2013 Apr;45(4):385-91, 391e1-2
23535732
Prostate. 2004 Dec 1;61(4):332-53
15389811
J Clin Oncol. 1996 Jun;14(6):1756-64
8656243
Br J Urol. 1983 Aug;55(4):408-12
6349745
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6094-9
17062685
Urol Res. 1987;15(3):155-60
3307087
Contemp Clin Trials. 2007 Feb;28(2):105-14
16807131
Endocr Relat Cancer. 2010 Oct 29;17(4):R305-15
20861285
BMC Urol. 2012 Feb 22;12:3
22353627
BMJ. 1997 Sep 13;315(7109):629-34
9310563
J Clin Oncol. 2008 Nov 10;26(32):5261-8
18794543
Pharmacol Ther. 1992 Dec;56(3):323-39
1301594
BJU Int. 2012 Jun;109 Suppl 6:1-12
22672120
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
26742998
Cancer Res. 1993 Oct 1;53(19):4573-81
8402630